Danish BioTech Samplix secures €3 million in new capital as part of a €25 million first close of financing round led by WLanholding GmbH to scale antibody discovery.
PRIVATEOct 28, 2026
Amount Raised
€3 Million
Round Type
Seed
Capital Region Of DenmarkBiotechnology
Investors
WLanholding GmbH
Description
Samplix has successfully secured €25 million in the first close of its financing round. This includes €3 million in new capital and €22 million in shareholder convertible bonds. The round is aimed at scaling their antibody discovery capabilities. WLanholding GmbH leads the round, with participation from major shareholders.
Who to call at Samplix, and when
A new round usually means Samplix is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Samplix raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Samplix, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Samplix. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Samplix
Location
Capital Region Of Denmark, Denmark
About
Samplix is a Danish BioTech company founded in 2013 that develops droplet microfluidics technology for functional single-cell analysis. Its core offering, the Xdrop platform, allows researchers to observe cell behavior within tiny double-emulsion droplets, facilitating high-throughput analysis. The technology addresses challenges in drug discovery, particularly in screening cells against difficult-to-target proteins. Samplix aims to make drug discovery faster, simpler, and more reliable by expanding its platform's adoption in the biopharmaceutical sector.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Samplix raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Capital Region Of DenmarkBiotechnology